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Preventative inhaled treatments preserve lung function and reduce exacerbations in Cystic Fibrosis (CF).
Self-reported adherence to these treatments is over-estimated. An online platform (CFHealthHub) has
been developed with patients and clinicians to display real-time objective adherence data from dose-
counting nebulisers, so that clinical teams can offer informed treatment support.
Methods
In this paper, we identify pre-implementation barriers to healthcare practitioners performing two key
behaviours: accessing objective adherence data through the website CFHealthHub and discussing
medication adherence with patients. We aimed to understand barriers during the pre-implementation
phase, so that appropriate strategy could be developed for the scale up of implementing objective
adherence data in 19 CF centres. 
Thirteen semi-structured interviews were conducted with healthcare practitioners working in three UK CF
centres. Qualitative data were coded using the Theoretical Domains Framework (TDF), which describes
14 validated domains to implementation behaviour change.
Results
Analysis indicated that an implementation strategy should address all 14 domains of the TDF to
successfully support implementation. Participants did not report routines or habits for using objective
adherence data in clinical care. Examples of salient barriers included skills, beliefs in consequences, and
social in uence and professional roles. The results also a rmed a requirement to address organisational
barriers. Relevant behaviour change techniques were selected to develop implementation strategy
modules using the behaviour change wheel approach to intervention development.
Conclusions
This paper demonstrates the value of applying the TDF at pre-implementation, to understand context and
to support the development of a situationally relevant implementation strategy.
Contribution to the literature
·     Research indicates that the implementation of healthcare innovations may be more likely to succeed
when context and theory are taken into consideration.
·     In this study, healthcare professionals identi ed barriers to two behaviours that were key to the
implementation of a national Cystic Fibrosis (CF) healthcare innovation. By coding barriers to the
Theoretical Domains Framework (TDF), a contextually relevant implementation strategy was developed,
with a focus on clinician behaviour change. 
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·     The study highlights the challenges CF teams face when implementing new remote monitoring of
medication adherence, and provides an important opportunity to apply the TDF in the pre-implementation
phase of a healthcare innovation.
Background
Cystic Fibrosis (CF) is a long-term condition affecting 10,000 people in the UK. Although survival in the
UK is rising, people with cystic  brosis (PWCF) typically die from lung damage at a median age of 47[1].
Preventative inhaled treatments preserve lung function by reducing infections [2–9]. Low adherence to
these treatments is associated with exacerbations and decreases in lung function [10–15]. Despite the
bene ts of treatment, objectively-measured adherence to preventative inhaled treatments is between 30
to 50%[16, 17]. Subjective self-report measurements – the norm in routine practice – substantially
overestimate adherence rates [16]. As a result, low adherence is largely invisible to care teams, who are
therefore unable to provide appropriate support to those who need it. 
Without access to objective adherence data for inhaled medications it is di cult for clinicians to identify
whether a patient is deteriorating due to non-adherence or due to novel pathology which requires a
change of treatment. To meet this challenge, we have worked with PWCF and healthcare practitioners to
co-produce an online platform (CFHealthHub). CFHealthHub displays real time objective adherence data
from dose counting nebulisers[18–21], allowing remote real time monitoring of patient adherence. A
national implementation exercise is now underway, supported by NHS England commissioning for quality
and innovation, in which objective adherence data will be embedded into routine CF care. In the  rst
phase of this work, we have created a digital learning health system - a cohort study with research,
implementation and quality improvement functions – in three UK CF centres (ISRCTN14464661).
Many innovations successful in a single centre or trial fail to be adopted across healthcare
organisations[25], particularly when the innovation is not adapted to the speci c context [26] in different
units. As such, implementation programmes need to identify the factors that in uence the performance
of the key behaviours that enable implementation, situated within the context of the target healthcare
provider. An understanding of the interactions between context and behaviour, used in combination with
theory, has the potential to optimise implementation strategy development [27–31].
Identifying the most appropriate theory for a given behaviour and context is challenging and choosing
one theory over another may result in key determinants of behaviour being missed [32].  The Theoretical
Domains Framework (TDF) [23, 33, 34]   is a synthesis of 33 different behaviour change theories, with 14
key domains that in uence an individual's Capability, Opportunity and Motivation to perform a Behaviour
(the COM-B model [35, 36]).  To implement the use of objective adherence data in routine practice, clinical
teams need to be able to perform two key behaviours #1) to routinely view patient’s objective adherence
data and #2) discuss objective adherence with the patient. These behaviours might be expected to be
sustained long term if they become established in local routines, with the hope that they become
habitual [37]. By identifying barriers and facilitators to performing the behaviours, through the
Page 4/18
identi cation of TDF domains, linked to COM-B, potential reasons for implementation failure can be
anticipated, understood, and addressed in advance.
The behaviour change wheel (BCW) is a tool to enable the design of interventions using a systematic
approach that is underpinned by the COM-B model. Here, we report a detailed situation analysis[38],
which used the TDF to identify potential pre-implementation barriers and facilitators of the desirable
behaviours and inform the development of an implementation strategy using the BCW [36, 39]. 
Methods
Study Design
This was a qualitative study using semi-structured interview data.  
Settings and participants
Participants (n=13) were healthcare practitioners from three participating CF centres, sampled from a
combined multi-disciplinary team (MDT) of 125. A further seven healthcare practitioners were
approached but were unable to participate due to time restrictions. At the time of this evaluation (April to
August 2018), one centre had been involved in the development of CFHealthHub over 12 months and
then started to use it in clinical practice and two of the three CF centres had taken part in a pilot trial of
CFHealthHub as part of which one member of the MDT has been trained to use the CFHealthHub website
and to deliver the intervention. All sites were therefore within the early stages of implementation.  The CF
population for the centres covered large geographical areas, across multiple counties. Each centre
supported between 175 to 250 PWCF, at the time of the study.
We purposively sampled from the MDT based on centre and professional category (Table 2). Recruitment
continued until the researchers determined that data saturation had been met, as de ned by
‘informational redundancy’ [40], whereby no new comments were identi ed in the interviews. 
Procedure 
The study team contacted healthcare practitioners by email. All participants gave informed consent prior
to the interview. Interviewers (CG, AP and DH) were known to three participants through wider project work
but were not from the same institution. The interview topic guide (additional  le 1) was based upon TDF
constructs [39] focusing on the behaviour of accessing adherence data through CFHealthHub (#1) and
discussing adherence with patients as part of routine practice (#2). Not all questions were relevant to all
participants; for example, at the time of the interviews the use of data to benchmark quality of care
between centres was not yet available to all members of the clinical team The interview guide was
developed by investigators with expertise in behaviour change (MA) and Cystic Fibrosis (MW) and piloted
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by one clinical member of staff. Interviews were conducted face to face or via a telephone. The duration
of interviews was between 17 and 55 (mean 37) minutes. All interviews were digitally recorded and
transcribed verbatim and imported into Nvivo 12 (QSR International). 
Analysis
Transcripts were analysed using Framework analysis [41] based on the TDF. Two researchers double-
coded each interview; where fragments were coded to more than one domain these were cross-indexed.
Researchers met regularly to discuss coding, data saturation and reach consensus on discrepancies. 
Implementation strategy development
Based on the  ndings of the framework analysis, members of the team, including a respiratory physician
(MW) and health psychologists (MA) developed an implementation strategy using the Behaviour Change
Wheel (BCW) approach [36]. Firstly, a behavioural needs analysis was completed for the behaviours of
routinely accessing objective adherence data (#1) and discussing adherence (#2) (table 1). Interview
data, mapped to TDF domains, were used to perform a behavioural diagnosis for behaviour #1 and #2,
allowing the researchers to identify what needs to change in order for the behaviours to be routinely
performed. From here, intervention functions were identi ed. Intervention functions are broad categories,
linked to the COM-B model. Within each intervention function there are multiple possible Behaviour
Change Techniques (BCTs). To ensure context-based decisions on intervention content and delivery, the
APEASE guidelines were applied to each of the nine potential intervention functions, speci ed in the BWC.
This allowed the researchers to evaluate functions for affordability, practicality, effectiveness,
acceptability, side effects/safety and equity. Having identi ed the barriers and relevant intervention
functions, behaviour change techniques (BCTs) were selected. These are displayed as implementation
‘strategy’ modules.  
Ethics
After review from the study’s Patient and Public Involvement group, ethical approval was obtained from
London-Brent Research Ethics Committee (ref 17/LO/0032).
Results
We present a summary of data by theoretical domains, ordered by the umbrella concepts, capability
opportunity and motivation (Table 3) before discussing the development of the implementation strategy.
We have combined the data for the two behaviours of focus.
Domains related to capability
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Overall, participants had some knowledge of the concept of nebuliser adherence, both in relation to the
challenges of nebuliser adherence and the impact on lung health. The disparity between subjectively
reported and objectively measured adherence was also frequently reported. By comparison, knowledge
about CFHealthHub was variable between centres and healthcare practitioners; some consultants were
unaware of patient facing CFHealthHub content but were aware that the platform displays adherence
data. The most engaged participants demonstrated a more insightful understanding, describing patient-
speci c content and its use for both patients and healthcare practitioners:
“…so it’s a monitoring tool I’d say as well as supportive tool for adherence” (S01F04).
            Most participants reported no formal training in using CFHealthHub, or in how to discuss
adherence with PWCF. Participants used skills from their professional training when discussing
adherence with patients:
“…I do it, I suppose in my own counselling type way…” (S01F01).
            Furthermore, skills and training in uenced participants' willingness to discuss adherence.
Participants with backgrounds in counselling and training in motivational interviewing reported this as a
facilitator for discussing adherence. Participants reported remembering (memory), paying attention and
decision processes in using adherence data as effortful. Discussing adherence with a PWCF was only
done when prompted by conversations with PWCF in clinic appointments, for example during changes in
prescribed medication. Even when adherence was remembered, participants did not necessarily access
the objective data from CFHealthHub. No one reported formal behavioural regulation strategies to ensure
adherence was discussed with PWCF. Where CFHealthHub was accessed as a team, this was during MDT
meetings and was driven by speci c individuals (see opportunity).
Domains related to opportunity
TDF domains relating to both physical and social opportunity featured prominently in the sample.
Participants described the physical barriers relevant to their centre’s environment, such as the availability
of clinic rooms in which to deliver adherence support. Access to computers and the internet also impeded
the ability to open the objective adherence data on CFHealthHub. All participants described time as being
a signi cant barrier for talking to PWCF about medication adherence (#2) and opening the objective
adherence data at meetings or with colleagues (#1):
“…meetings are quite quick and then there are other things that we need to talk about and we don’t
necessarily have time to factor in the adherence in it in a detailed way”. (S01F02)
Participants thought that physiotherapists and nurses had more contact time with patients than
consultants, and therefore had more time to use CFHealthHub (links to professional role). 
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In addition, all centres reported that limited staff capacity, particularly during the winter months, was a
barrier to both behaviours. However, participants did note that CFHealthHub would make accessing
adherence data easier than previous systems[1]. At least one in uential  gure, or “CFHealthHub
Champion” from each centre was identi ed. A factor that appeared to be associated with social
in uences was how passionate the individual was about CFHealthHub. Participants also felt that doctors
and consultants had the most in uence in centres and were an important factor in the adoption of
adherence data into practice. Some participants reported feeling that they were not individually able to
implement change in their centre; they believed change would require team effort. 
Domains related to motivation 
Professional role featured heavily as a theme in determining who accessed CFHealthHub and which
individuals in a centre provided adherence support to patients. Those who reported they did access the
objective adherence data on CFHealthHub and have adherence discussions did so because “it is part of
my job isn’t it?” (S03F01).   Each team reported an individual as being responsible for opening adherence
data. This meant that the behaviour of opening adherence data fell down when the individual was
unavailable “We planned having it in every MDT meeting, … we feel slightly guilty when [name] isn’t here
‘cause she’s the one who usually sets that for us” (S01F02).
Participants reported the goal that CFHealthHub would be used routinely in MDT meetings, but had
varying levels of intentions to use CFHealthHub. Physiotherapists reported that they intended to access
adherence, whereas Consultants generally stated they might access adherence data themselves or
through a colleague. However, Consultants report that they did not have intentions of performing the
second behaviour of delivering adherence support. 
“I don’t think I use it with patients, cause I don’t think I have the time to sit and use it with patients; plus it’s
mainly delivered probably by the physios (yeah) at the moment in our service, or [name] might be working
with one or two. So, because that you already know that they’re doing with it, I’ll talk about their
adherence, but I’m not gonna, I don’t sit down with  (and open it up)” (S01F05).
Participants discussed a range of beliefs about the power of adherence data and CFHealthHub and the
consequences of using these tools. Although these was a consensus that using CFHealthHub and
discussing adherence could improve patient care and could increase adherence, participants felt this
would be limited to certain groups of patients or that they would see small incremental changes “…If you
get people who are at 30% up to 40% that’s good and if you get people who are at 55% up to 65% that’s
good and that’s where I think the bene t’s going to be” (S02F03). In addition, healthcare practitioners
believed that adherence data would not be helpful for patients with complicated home lives. The
circumstances and their willingness to engage with adherence were also reported as barriers to
supporting adherence, suggesting that they were reluctant to discuss this with everyone.
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“I suppose both depending on what sort of place they’re in at that time, how their mood is… Some people
we’re building relationships with when they  rst come to us and we don’t want to be heavy...” (S01F01)
Some participants perceived negative consequences. These participants were concerned objective
adherence data could become a tool for “telling off” patients. This belief was in uenced by the
knowledge that that the clinical team hadn’t received adequate training in accessing and using adherence
data. This was thought to impact on the capability of the team to use the data in a positive, patient
centred way. 
“… I think without the right training and support with the team is that actually it could then be used in a
negative way with the patient. So actually as a tool to tell patients off …” (S03F01).
Participants received some reinforcement for using CFHealthHub. Viewing improvement in patient’s
adherence was felt to be rewarding. Participants also reported positive emotions when seeing
improvements in PWCF adherence. 
[insert table 3] 
Implementation strategy development
All 14 domains were relevant to routinely access objective adherence data (#1); six were relevant to
discussing adherence with patients (#2) (Table 4 and 5). Intervention functions de ned in the BCW were
considered in relation to the behavioural needs assessment (Table 1) and reported barriers (Table 4 and
5). Discussions around the implementation intervention considered the needs of different professional
roles, with the reported barriers to performing each of the behaviours. The intervention functions were
evaluated using the APEASE guidelines, which led to the rejection of three intervention functions, as likely
to be impractical (restriction), ineffective (incentivisation) or unacceptable (coercion), see table 6 for
speci c reasoning. Table 7 provides more detail on the selected proposed intervention functions that
would go on to help identify suitable BCTs. Six intervention functions were selected by the researchers as
suitable (training, education, environmental restructuring, enablement, modelling and persuasion), based
on the needs assessment (Table 1). The intervention functions were further de ned, leading to the
selection of 31 speci c functions for routinely accessing objective adherence data (#1) and 12 for
discussing adherence (#2) (Table 7). Each BCT was discussed in relation to the two behaviours and
identi ed barriers. This led to the identi cation of BCTs that the researchers deemed useful. The
practicality, resources and expertise from the central study team were also considered when selecting and
grouping the BCTs into potential implementation modules (Tables 8 and 9). 
Implementation strategy modules
Tables 8 (#1) and 9 (#2) demonstrate how intervention functions, identi ed from barriers reported in
interview data, link to proposed BCTs. On this basis, we have put together the following modules:
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Educational/Training package
(#1) To address the varied training and education barriers to routinely using objective adherence data, a
face to face and online educational training package would be provided, with the aim to provide practical
support, such as instructions on how to perform the behaviours and information about others approval of
the behaviour, for example local endorsement by members of the clinical team. As participants reported a
varied understanding of the relevance of objective adherence data to CF care, the training package would
focus on presenting information about the consequences of non-adherence for the PWCF and the
relevant impact on the clinical team. To address social in uence barriers such as lack of senior
management support, it is important that a Consultant Physician provides demonstrations of the
behaviour during these sessions and endorses accessing adherence data (#1), alongside credible sources
of information and the opportunity to rehearse the behaviours.
(#2) The same module principals should be applied, however focused on delivering non-judgemental
conversations and behaviour change techniques, as described in CFHealthHub intervention development
 [42, 43]. 
Quality Improvement Cycles
(#1) Quality improvement (QI) methods were identi ed as a potential strategy to address centre speci c
barriers and provide feedback on the frequency of the performance of the behaviours at an individual and
centre level. QI can be used to perform a number of BCTs (see table 8) and is adaptable to individual
centre context [44]. The implementation will use The Dartmouth Institute QI methodology, allowing the
BCT problem solving, through process mapping and Plan Do Study Act (PDSA) cycles. These techniques
will allow small behavioural experiments for change to be implemented, measured (providing feedback)
and revised as required. As well as supporting centres to address environmental issues and improving the
e ciency of the team, this strategy could be used to address speci c concerns. For example, where the
belief in prescription accuracy is a barrier, then the team would use quality improvement PDSA cycles to
address their centre prescription processes and integrate updating CFHealthHub prescriptions that drive
adherence data accuracy, into current practices. QI should be data driven [45, 46] to provide measurable
feedback. To overcome the lack of behavioural regulation, healthcare practitioners should be given
feedback on their own performance of behaviour #1 through frequency of website clicks into objective
adherence data, collected as part of PDSA cycles.
(#2) Relevant CFHealthHub page clicks should be fed back to healthcare practitioners delivering
adherence discussions. Barriers identi ed such as clinic space and time can be addressed through QI
cycles, in the way described for #1.  
Cystic Fibrosis Improvement Collaborative as an improvement support module 
Creating an improvement collaborative would link CF centres into a community of practice and provide a
platform for sharing past successes and learning from across the CF healthcare system that can solve
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implementation barriers using ideas that have worked elsewhere. For example, interview data indicated
that there were barriers to lack of support across senior management and colleagues (#1 and #2).
Participants also reported concerns that adherence support (#2) was only suitable for PWCF without
complicated home lives, and this belief hindered healthcare professional’s motivation to discuss
adherence. Taking these issues to the collaborative for consideration, would allow information about
what others think of the behaviour, including how PWCF perceive their care teams using their data (#1)
and supporting adherence (#2) to be provided. This would also enable healthcare practitioners to view
both behaviours being performed. 
Planning, Routine and Habits 
(#1) Lack of routine and habit was reported by all centres and as such made performing both behaviours
effortful and unreliable.  Healthcare practitioners lacking established routines or habits for regularly
accessing adherence data on CFHealthHub, could be identi ed through website click analytics and self-
report. Support would be provided to set achievable targets, focusing on frequency of accessing
adherence data. Healthcare professional would be supported to identify prompts or cues in the
environment for the behaviour and then action plan performing the behaviour. Prompting rehearsal and
repetition in the same context is thought to support habit formation. By supporting healthcare
practitioners to build robust habits to behaviour #1, barriers related to ‘forgetting’ and the effort involved
in opening CFHealthHub at clinical encounters could be addressed. 
(#2) Healthcare practitioners would be supported by CFHealthHub champion to plan when and where
they would deliver adherence discussions. It is not expected that ‘habits’ would be created in discussing
adherence, as replicability of the behaviour in similar situations is thought to be unlikely. 
[1] The previous system required multiple steps and did not allow the PWCF or clinician to see the data
before the consultation. The device had to be brought to clinic, put into a docking device, the data
downloaded and the clinician to manually calculate adherence based on prescription. They would then
report back to the PWCF during the clinic appointment. 
Discussion
Median adherence in Cystic Fibrosis is 30% but without measuring adherence clinical teams cannot
determine which patients are deteriorating due to non-adherence and which are deteriorating due to novel
pathology.   This paper identi ed the barriers and facilitators for CF healthcare practitioners to implement
two behaviours, #1 accessing objective adherence data from the website and #2 discussing adherence
with PWCF as part of routine clinical care, through interviews with CF specialist healthcare practitioners.
The barriers for each behaviour were mapped to intervention functions and BCTs, using the behaviour
change wheel (BCW) [36] which formed the basis of an implementation strategy. As well as identifying
the challenges facing CF teams, this paper provides an example of the use of the TDF and BCW to
systematically identify facilitators and barriers and derive implementation strategies. 
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The key goal of successful implementation is to select strategies that are appropriate for the
organisations and stakeholders [47]. Although methods such as quality improvement, can be effective in
implementing change at a local setting, it is not likely to be su cient to ensure new practices diffuse or
scale up across organisations[48]. Changing routine clinical practice in CF also involves behaviour
change at the level of the healthcare practitioner. Therefore, an implementation intervention must be
aimed at the needs of the individuals, rather than relying on system change only.
Habit or routine offers a sustainable mechanism for behaviour change in healthcare practitioners [49, 50].
Once established, a routine of accessing adherence data (behaviour #1)  might create the habit that
would lead to  automaticity that would override the requirement for future motivation [51] and may be
resilient  in the face of increased work related stressors [52]. The implementation package seeks to
address fundamental barriers to behaviour #1.  If barriers are removed and the behaviour is successfully
repeated  the establishment of a routine or habit will reduce the burden of behaviour #1 and repetition will
be more likely [53]. 
The same implementation strategy modules can be applied to the complex behaviour of discussing
adherence with patients (#2). It is not expected that ‘habit’ would be relevant to behaviour #2, as
healthcare practitioners are required to make a judgement about the suitability and content of the
discussion on a per person basis. However, planning for the behaviour #2 is important to enable the team
to identify who, where and when adherence discussions will be delivered. We hypothesise that reducing
the barriers described in this paper could be su cient to enable increases in adherence discussions
within routine practice. Future research should aim to address this question.
While the interviews were conducted on a relatively small number of participants at a limited number of
centres, given the narrow study aim, speci city of the sample and the use of established theory [54], the
number of interviews is likely adequate to understand common barriers to programme implementation.
Multiple coding using a validated framework[34, 55] with the input of an experienced health psychologist
increases the trustworthiness of the  ndings. 
Together, the three sites function as a ‘scalable unit’ which can be used to assess the necessary
requirements for best-practice implementation, and to test the processes and infrastructure needed to
achieve full-scale integration of the intervention[56].  A further 19 NHS Trusts expressed an interest in
implementing CFHealthHub from June 2019. Conducting this analysis at the outset of the pre-
implementation has maximised the opportunity to formulate an implementation strategy that will be
applicable during scale up[57]. The next step will be to test this empirically devised implementation
strategy and identify the elements which succeed or fail. 
Conclusion
We have devised an implementation strategy to increase and sustain two target behaviours, opening
objective adherence data and initiating adherence discussions, both of which are required for
implementing the web application ‘CFHealthHub’. The study identi ed potential pre-implementation
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facilitators and barriers, reported by CF healthcare practitioners and sensitive to local context.  The
resulting implementation strategy was developed using the TDF and BCW, demonstrating that the TDF
can be used to develop implementation strategies. The success of this speci c implementation
intervention will be evaluated in future longitudinal research in up to 19 UK CF centres.
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